Glaxosmithkline Plc (GSK)
$40.62 0.35 (0.87%)
11:50 EDT GSK Stock Quote Delayed 15 Minutes
Previous Close $40.27
Market Cap 100.73B
PE Ratio 97.64
Volume (Avg. Vol.) 1.08M
Day's Range 40.36 - 40.69
52-Week Range 36.41 - 42.32
Dividend & Yield 2.14 (5.27%)
GSK Stock Predictions, Articles, and Glaxosmithkline Plc News
- From InvestorPlace
- From the Web
These undervalued stocks have been hit hard lately, but they still have what it takes to make a comeback, making them solid stocks to buy.
These ten stocks aren't exactly household names, but they each deserve a spot in a list of small-cap stocks to buy now for traders that can deal with the risk for the potential of high reward.
Think all blue-chip stocks are safe buys at any time? Think again. These companies may be about to stumble, if they haven't already.
These three biopharma stocks to buy should help investors maintain strength amid any potential chaos in 2019.
GlaxoSmithKline (GSK) stock is up today on news of a new joint venture with Pfizer (PFE) for a consumer healthcare business.
The stock charts of ROST, D and MS are shaping up as the top trading prospects as December's action gets going.
Tesaro stock was flying high on Monday with news that GlaxoSmithKline (GSK) is planning to acquire it in a deal worth $5.10 billion.
If you're looking for the best dividend stocks with high yields and solid growth prospects, don't limit yourself -- look overseas.
These seven healthcare stocks are coming to life Monday. Here's how to play these companies without getting burnt.
GlaxoSmithKline pays shareholders a solid dividend yet the company is not just for income investors. In the next few years, growth in the consumer unit will lead to strong cash flow, raising the chances of dividend hikes for GSK stock.
Small-cap stocks have been on a tear of late. Take the hint, and start your search with these seven top prospects.
International dividend stocks should make up a hefty portion of your portfolio, as you need them to smooth out the sort of stateside volatility we're experiencing right now.
In the first six months of the year, the FDA grants approval to 17 new treatments. Compare Brokers....
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well. Compare Brokers....
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
GlaxoSmithKline (GSK) stock was down on Wednesday following the release of an earnings report that misses estimates for the first quarter of 2018.
Often there are signs leading up to dividend stocks cutting their payouts. If you own any of these 7 you'd be better off moving your money elsewhere.
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by....
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018.
From Seeking Alpha
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!